Welcome to this week’s edition of 18 Share Tips – our weekly selection of top ASX shares, chosen by leading analysts, that we think are worth considering.
This week Blake Halligan of Catapult Wealth, Mark Gardner of MPC Markets and Remo Greco of Sanlam Private Wealth share their ‘Buy’, ‘Hold’ and ‘Sell’ recommendations.
Please note these share tips are simply recommendations and are in no way intended as financial advice. These share tips are general advice and don’t take into account any individual’s financial situation. Investors are advised to seek professional financial advice before investing.
Early Access to 18 Share Tips
Every Monday at 9AM, thousands of investors scramble to read the same tips at the same time. Prices move. Opportunities disappear. You’re always one step behind.
But with The Bull Premium you get access to 18 Share Tips on Friday morning, giving you 3 extra days to prepare.
So while others read Monday’s tips, you’re already positioned to win.
Blake Halligan, Catapult Wealth

BUY RECOMMENDATIONS
BUY – Pro Medicus (PME)
Pro Medicus develops advanced medical imaging software used by major hospitals and radiology groups globally. The company reported a strong first half result in fiscal year 2026, with revenue up 28.4 per cent to $124.8 million and underlying profit before tax rising 29.7 per cent to $90.7 million. In March, PME secured two important contract renewals worth a minimum of $40 million, both at higher transaction fees, signalling strengthening pricing power. With an underlying earnings before interest and tax margin at 73 per cent and cash of $222 million, PME remains financially robust. Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition.
BUY – Betashares S&P/ASX Australian Technology ETF (ATEC)
This exchange traded fund invests in Australian technology companies. ATEC has experienced a material pullback alongside the broader Australian technology sector, creating an attractive entry point for long term investors. Share prices in several of its key constituents, including Xero, WiseTech Global, Pro Medicus and REA Group, have fallen significantly despite stable earnings trajectories and ongoing revenue growth across the sector. Market concerns surrounding artificial intelligence disruption appear overdone, in my view, particularly given the high costs of switching software platforms. Despite weaker sentiment, fundamentals are largely intact. In our view, an appealing opportunity exits to gain exposure to high quality Australian technology names through ATEC.
HOLD RECOMMENDATIONS
HOLD – Nick Scali (NCK)
This furniture retailer operates in Australia, New Zealand and the UK. The company delivered a strong first half result in fiscal year 2026, with group statutory net profit after tax of $41 million beating upgraded guidance. The gross margin improved to 65.4 per cent. However, Australian and New Zealand sales in January were lagging revenue growth of 13.1 per cent in the first half. UK operations continue to improve, though still at a small scale. Solid margins but weaker confidence in near term growth leaves the stock appropriately valued.
HOLD – Virgin Australia Holdings (VGN)
The Australian airline delivered a strong result in the first half of fiscal year 2026, with underlying earnings before interest and tax increasing by 11.7 per cent to $490 million. Revenue per available seat kilometre (RASK) was up 6.4 per cent. The group’s transformation program delivered more than $200 million in gross benefits. The company has now exhausted tax losses and will begin paying tax, with franking credits at $94 million. While demand and yields remain supportive, rising expenses suggest a balanced hold stance.
SELL RECOMMENDATIONS
SELL – Fletcher Building (FBU)
FBU makes and distributes building materials and provides construction, infrastructure and residential development services. Its first half result in fiscal year 2026 highlighted ongoing pressure. Earnings before interest and tax from continuing operations before significant items was $NZ145 million, which was marginally below expectations. Net debt remains elevated and the company has trimmed capital expenditure, underscoring management’s caution. The company has announced the sale of its construction division for $NZ315.6 million. However, broader conditions in New Zealand remain subdued, and a meaningful earnings recovery isn’t expected until calendar year 2027. With limited catalysts and no dividend support, better opportunities present elsewhere.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - market-leading social trading platform - Read our review
SELL – Guzman Y Gomez (GYG)
GYG is a Mexican themed restaurant chain. Although network sales grew 18 per cent to $682 million in the first half of fiscal year 2026, several metrics signal caution. Segment underlying EBITDA in the United States posted a loss of $8.3 million. The stock continues to trade on high price/earnings multiples. In our view, execution risks are rising and margins are under pressure. Investors may find better opportunities by re-allocating funds to alternative investments. GYG shares have fallen from $31 on March 31, 2025 to trade at $16.81 on March 26, 2026.
Mark Gardner, MPC Markets

BUY RECOMMENDATIONS
BUY – Telix Pharmaceuticals (TLX)
The company’s prostate imaging agent is generating strong sales in the United States. The near term story is about brain cancer imaging. The company recently re-submitted its drug application to the US Food and Drug Administration (FDA) for Pixclara, an imaging agent for a particularly aggressive form of brain cancer. The FDA has given it priority status, and Telix has gone through a formal meeting to address every question raised in its previous application. In our view, a re-submission isn’t a setback, but the last step before approval. We believe the market isn’t pricing in the benefits of a potentially successful FDA outcome.
BUY – Pro Medicus (PME)
The company provides medical imaging software and services to hospitals and healthcare groups across the world. Its software has quietly become the dominant choice across some of the largest hospital networks in the United States. The product is faster, more scalable and modern than what its competitors offer. Artificial intelligence is built in, so it complements the business. The share price plunge has been driven by broad technology sentiment as opposed to issues with the business. Earnings are still growing and the company still wins major new hospital contracts. In our view, the market has handed investors an appealing entry point into one of the best software businesses on the ASX. We retain our buy recommendation.
HOLD RECOMMENDATIONS
HOLD – Northern Star Resources (NST)
The gold company has been punished for downgrading gold production. Mechanical and equipment issues at its flagship Kalgoorlie operation have been frustrating, and the market has lost patience. However, Northern Star still owns one of the best gold assets in the world and its long term reserve base is intact. The conflict in Iran has also generated indiscriminate selling in gold miners that history tends to show as a buying opportunity. Operational problems are temporary and we expect the gold price to improve moving forward.
HOLD – BHP Group (BHP)
The global miner delivered a strong half year result in fiscal year 2026. Copper delivered the majority of earnings for the first time in the company’s modern history. The dividend was above expectations. The balance sheet is in good shape. The conflict in Iran has rattled commodity markets, and BHP shares have fallen heavily. Most of BHP’s output goes to Asia, not through the Strait of Hormuz. The market is selling the ticker, not the fundamentals. We suggest adding on weakness, and holding for an upgrade when the conflict ends.
Although Mark Gardner has listed BHP Group as a ‘Hold’, Remo Greco has listed it as a ‘Buy’. Each analyst’s views are their own and they will not always agree.
SELL RECOMMENDATIONS
SELL – Appen (APX)
Appen is a former market darling of technology stocks. The company built a global business providing the human-labelled data that artificial intelligence systems needed to learn. Demand seemed unlimited and the share price reflected optimism, trading above $35 in July 2020. While Appen pays workers to label data, artificial intelligence is getting better at doing the role itself. Synthetic data generation, automated labelling pipelines and AI systems that can evaluate their own outputs are advancing rapidly. In our view, the recent share price bounce reflects short term sentiment around AI investment themes rather than an improvement in the structural outlook. The company’s statutory net loss after tax of $US21.8 million in full year 2025 was up from a $US20 million loss in the prior corresponding period. The shares were trading at $1.565 on March 26, 2026.
SELL – MA Financial Group (MAF)
This global alternative asset manager has grown quickly and, to its credit, delivered strong underlying earnings growth in full year 2025. It specialises in private credit, real estate, hospitality and corporate advisory. There is genuine quality here, and management is transparent. Our concern is MAF’s exposure to the private credit market in the United States, which is increasingly under pressure. We have placed private credit on our highest alert. MAF is well managed and the team is carefully navigating the private credit market. But the business is exposed to a sector under pressure, which we believe is reflected in the company’s share price. The shares have fallen from $11.26 on February 18 to trade at $7.565 on March 26. We prefer to reduce exposure to private credit managers and direct that capital elsewhere.
Remo Greco, Sanlam Private Wealth

BUY RECOMMENDATIONS
BUY – BHP Group (BHP)
The current volatility presents investors with an opportunity to buy this global miner at attractive prices. The recent BHP announcement of Brandon Craig replacing the retiring Mike Henry as chief executive is a good appointment. Craig was responsible for the company’s Americas business, and that’s where the growth is likely to come from in the medium term. Group revenue in the first half of 2026 was up 11 per cent on the prior corresponding period and profit from operations was up 34 per cent.
Although Remo Greco has listed BHP Group as a ‘Buy’, Mark Gardner has listed it as a ‘Hold’. Each analyst’s views are their own and they will not always agree.
BUY – Ramsay Health Care (RHC)
The private hospital operator posted a better than expected first half year result for fiscal year 2026. Revenue of $9.3 billion from contracts with customers was up 9.7 per cent on the prior corresponding period. Underlying net profit after tax of $171.7 million was up 8.1 per cent. RHC is spinning off its European business, which we believe paints a brighter outlook. The fully franked interim dividend of 42.5 cents was up 6.3 per cent and potentially points to a stronger final dividend for the full year.
HOLD RECOMMENDATIONS
HOLD – Goodman Group (GMG)
GMG is a global industrial property group managing more than $87.4 billion. The company is generating growth in the data centre space. The company, involving partners, announced work in progress of $14.4 billion in 12 countries across 51 projects at its first half results in fiscal year 2026. The company expects work in progress to increase to about $18 billion by June 30, 2026. High occupancy was maintained at 95.9 per cent. Company initiatives are likely to take time to lift profitability, but we believe patient investors will be rewarded.
HOLD – ALS Limited (ALQ)
ALS is a global player offering laboratory testing for the mining sector and the life sciences industry. Both sectors are enjoying strong demand. The mining sector is ramping up gold and copper exploration. In life sciences, the growing middle classes across emerging markets are demanding cleaner food and drug products. The company operates in more than 50 countries and expects to generate growth of between 10 per cent and 15 per cent per annum over the next three years.
SELL RECOMMENDATIONS
SELL – Transurban Group (TCL)
Transurban operates toll roads across Australia and North America. Average daily traffic across all markets increased by 2.5 per cent in the first half of 2026. The company generated proportional total revenue of $2.019 billion in the first half of 2026, up 6 per cent on the prior corresponding period. However, proportional operating costs of $474 million were up 4.6 per cent. Substantial group debt in December 2025 was marginally higher than in June 2025. The company’s share price is volatile, but stuck in a trading range in the absence of a meaningful catalyst for a share price break to the higher side. In our view, other companies offer more appealing returns.
SELL – Commonwealth Bank of Australia (CBA)
The bank is a quality company and a staple in investor portfolios. It has established a strong track record of performance over many years. The company delivered a 5 per cent increase in statutory net profit after tax in the first half of fiscal year 2026. However, the dividend yield was trading below 3 per cent on March 26, so better income is available elsewhere. The conflict in Iran suggests a possibly slowing global economy likely to impact credit growth in Australia’s higher interest rate environment. CBA is trading at a premium to peers, so it may be time to consider reducing exposure in this volatile environment.
The above recommendations are general advice and don’t take into account any individual’s objectives, financial situation or needs. Investors are advised to seek their own professional advice before investing. Please note that TheBull.com.au simply publishes broker recommendations on this page. The publication of these recommendations does not in any way constitute a recommendation on the part of TheBull.com.au. You should seek professional advice before making any investment decisions.
